---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-021990"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T02:05:43.035593+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alumis reports positive 52-week Phase 2 OLE data for ESK-001 in plaque psoriasis at AAD 2025

## Summary
- ESK-001 40 mg BID achieved PASI 90 61.3%, PASI 100 38.8%, sPGA 0 38.8% at Week 52 (mNRI, n=80).
- Responses sustained or improved vs Week 12; 80% of ≥PASI-75 responders at Week 12 maintained or improved at Week 52.
- No new safety findings; most TEAEs mild-to-moderate and self-limited.
- Phase 3 ONWARD program ongoing; topline data expected Q1 2026.
- Patient-reported outcomes: DLQI 0/1 61.3% and itch NRS≤4 81.3% at Week 52.

## SEC filing metadata
- accession: 0001104659-25-021990
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/0001104659-25-021990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-021990
- JSON: https://secwatch.observer/filing/0001104659-25-021990.json
- Plain text: https://secwatch.observer/filing/0001104659-25-021990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.